Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Identifying surrogate markers for survival in MM

David Siegel • 13 Sep 2019
IMW 2019
Multiple Myeloma

David Siegel, MD, PhD, John Theurer Cancer Center, Hackensack, NJ, discusses the evergrowing need to identify novel surrogate markers for survival, including MRD and other endpoints, such as time to MRD negativity relapse, among others presented at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from David Siegel

Does maintenance therapy increase overall survival in myeloma? 10:09
Does maintenance therapy increase overall survival in myeloma?
Andrew Spencer et al. • 13 Sep 2019
Transplantation in modern myeloma therapeutics 12:34
Transplantation in modern myeloma therapeutics
Andrew Spencer et al. • 13 Sep 2019
The role of transplantation in the treatment of multiple myeloma 5:24
The role of transplantation in the treatment of multiple myeloma
David Siegel • 13 Sep 2019
CAR T-cells in myeloma: exploratory targets & payment models 9:28
CAR T-cells in myeloma: exploratory targets & payment models
Andrew Spencer et al. • 7 Sep 2018

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals